[Paper] ATTAIN-1 — an oral pill with no food restrictions is a bigger deal than the % suggests
Confession thread, sort of.
I went from 12.5mg to 5mg much faster than I should have because the scale had stalled and I got impatient. The stall broke about 23 weeks later, at which point I had no way of knowing whether the dose increase did anything or whether it would have broken anyway.
So now I have injection-site soreness I did not need and a data point I cannot interpret. Two lessons in one.
Posting it in the hope that somebody at week 45 reads it before doing the same thing.
best — the order this archive was captured in
Flair changed to match the content. Read the sidebar before posting next time and we are square.
Mechanistically the bit that matters is TRIUMPH. It explains most of the early profile and a decent chunk of the outcome.
dropout handling matters, especially on GI-heavy populations
the relative risk reduction in headlines is not the whole story
Strongly agree. Phase 2 is investigational, not conclusive.
STEP, SURMOUNT, SURPASS, SELECT, FLOW, TRIUMPH — read the appendix
Flair changed to match the content.
Adding to this: SURMOUNT is doing more work than the comment implies.
dropout handling matters, especially on GI-heavy populations
the relative risk reduction in headlines is not the whole story
the 20 week readout is different from the 14 week readout
Phase 2 TRIUMPH looked amazing. Phase 3 trials are harder. Do not anchor on phase 2 readouts.
Slight fix: the number was 93.7, not 99.3. Decimal point, but a fairly consequential one.
Slight fix: the number was 93.7, not 99.3.
Disagree on that part. 96.8% and 96.2% on the same vial is normal.
the relative risk reduction in headlines is not the whole story
Yeah, absolute numbers matter more than the press release.
absolute risk reduction, not relative risk reduction, that is how you decide
number-needed-to-treat is the house dialect
give the trial name, phase, n, and primary endpoint in the body
Rodent data is rodent data. Dose scaling is not linear and the models tell you what to investigate, not what to expect.
SURMOUNT-4 discontinuation arm showed regain. That is the reality of a chronic disease treatment, not a failure.
phase 2 is not phase 3, smaller n and shorter trial
the discontinuation arms are the interesting part, not the SURMOUNT endpoints
the 16 week readout is different from the 12 week readout
phase 2 is not phase 3, smaller n and shorter trial
- 1the 20 week readout is different from the 14 week readout10 comments in this branch · started by u/aurel_mwangi
- 2Flair changed to match the content. Read the sidebar before posting next…9 comments in this branch · started by u/trialwatch_theo